SCHEDULE: Janus Henderson Boosts Benitec Biopharma Stake to 11.3%

Janus Henderson Group plc and its affiliates have reported an aggregate beneficial ownership of 11.3% in Benitec Biopharma Inc.'s common stock.

Summary

• Janus Henderson Group plc, a Jersey-based entity, reported beneficial ownership of 25,600,210 shares of Benitec Biopharma Inc. common stock.
• This represents 11.3% of the class of securities.
• Janus Henderson Biotech Innovation Master Fund Ltd, a Massachusetts-based entity and an indirect subsidiary, reported beneficial ownership of 2,193,481 shares, representing 8.6% of the class.
• The filing indicates that JHIUS, an indirect subsidiary of Janus Henderson Group plc, may be deemed to beneficially own 2,902,794 shares, also representing 11.3% of the class.
• The shares are held with shared voting and shared dispositive power by both reporting persons.
• The filing date is August 14, 2025, for an event that occurred on June 30, 2025.

Sentiment

Score: 6

Explanation: The filing indicates a significant and passive stake by a major institutional investor, which can be viewed as a positive signal of confidence in the company, although it does not provide operational or financial performance details.

Positives

• A significant institutional investor, Janus Henderson Group plc, maintains a substantial 11.3% stake in Benitec Biopharma Inc., indicating continued interest.
• The beneficial ownership is held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Negatives

• No specific negative information regarding Benitec Biopharma Inc. is disclosed in this beneficial ownership filing.

Risks

• This filing does not contain specific risk factors related to Benitec Biopharma Inc.'s operations or financial health. It is a disclosure of beneficial ownership.

Future Outlook

This filing, a Schedule 13G, does not provide any forward-looking statements or guidance regarding Benitec Biopharma Inc.'s future operations or financial performance.

Industry Context

This filing reflects a passive investment by a major asset manager in the biopharma sector, consistent with institutional interest in companies within this industry. It does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• This filing is a standard disclosure of beneficial ownership by an institutional investor. It does not provide performance metrics for comparison to industry standards or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Janus Henderson Group plc may influence investor perception and potentially provide a degree of stability or confidence in the stock.

Key Dates

Keywords

Benitec Biopharma Inc., Janus Henderson Group plc, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Biopharma, Institutional Investor